Sanjay Popat

30.3k citations

372 papers · 13.5k indexed · 7 hit papers · h-index 42

Impact in

Oncology top 0.1%
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
Pulmonary and Respiratory Medicine top 0.1%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Occupational and environmental lung diseases

Papers in

Pulmonary and Respiratory Medicine 285
- Lung Cancer Treatments and Mutations 218
- Lung Cancer Diagnosis and Treatment 72
- Occupational and environmental lung diseases 49
- Pleural and Pulmonary Diseases 29
Oncology 219
- Lung Cancer Research Studies 84
- Colorectal Cancer Treatments and Studies 62
- Cancer Immunotherapy and Biomarkers 41

Co-authors: Richard S. Houlston Solange Peters Richard Hubner Keith M. Kerr Martin Reck Silvia Novello Tony Mok Corinne Faivre‐Finn
Journals: Annals of Oncology (53 papers)Lung Cancer (49 papers)Journal of Clinical Oncology (45 papers)Journal of Thoracic Oncology (42 papers)European Journal of Cancer (16 papers)
Partner nations: United Kingdom United States France

In The Last Decade

Sanjay Popat

349 papers receiving 13.3k citations

Hit Papers

7 papers align trajectories log scale

ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group 2022 · 355 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2022 Annals of Oncology
2022 Annals of Oncology
2018 Annals of Oncology
2016 Annals of Oncology
2014 Annals of Oncology
2013 Annals of Oncology
2005 Journal of Clinical Oncology

Peers

Countries citing papers authored by Sanjay Popat

Since Specialization

Citations

This map shows the geographic impact of Sanjay Popat's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sanjay Popat with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sanjay Popat more than expected).

Fields of papers citing papers by Sanjay Popat

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sanjay Popat. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sanjay Popat. The network helps show where Sanjay Popat may publish in the future.

Co-authors

The 25 scholars most cited alongside Sanjay Popat, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Sanjay Popat Line = papers co-authored together Sanjay Popat links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Utilizing ctDNA to discover mechanisms of resistance to targeted therapies in patients with metastatic NSCLC: towards more informative trials Nature Reviews Clinical Oncology ·Sophie M. Ernst, Mihaela Aldea, Jan H. von der Thüsen, Adrianus J. de Langen, Egbert F. Smit, Marthe S. Paats, Joachim G.J.V. Aerts, Laura Mezquita, Sanjay Popat, Benjamin Besse, Jordi Remón, Christian Rolfo, Hendrikus J. Dubbink, Anne‐Marie C. Dingemans	2025	1
2	Phase 2 study to evaluate the novel mitochondrial PRX3 inhibitor, RSO-021, as an intrapleural monotherapy and in combination with IV paclitaxel in patients with malignant pleural effusion due to mesothelioma or another advanced solid tumor. Journal of Clinical Oncology ·Sean Dulloo, Simon Lord, Dean A. Fennell, Fiona Thistlethwaite, Nick Maskell, Sanjay Popat, Kevin G. Blyth, Peter W. Szlosarek, Avinash Aujayeb, Sohail Rooman Javed, Julio Herrero Colomina, Brian Cunniff, Jarrett Duncan, Philippa Graham, Alice Bexon, George N. Naumov, James Spicer	2024	2
3	Data set for the reporting of lung cancer: recommendations from the International Collaboration on Cancer Reporting (ICCR) Histopathology ·Wendy A. Cooper, Fleur Webster, Kelly J. Butnor, Fiorella Calabrese, Teh‐Ying Chou, David Hwang, Izidor Kern, Sanjay Popat, Lynette M. Sholl, Yasushi Yatabe, Andrew G. Nicholson	2024	0
4	Lung Cancer Related Thrombosis (LCART): Focus on Immune Checkpoint Blockade Cancers ·Andriani Charpidou, Grigoris Gerotziafas, Sanjay Popat, António Araújo, Arnaud Scherpereel, Hans‐Georg Kopp, Paolo Bironzo, Gilbert Massard, David Jiménez, Anna Falanga, Αναστάσιος Κόλλιας, Konstantinos Syrigos	2024	3
5	NTRK gene fusion testing and management in lung cancer Cancer Treatment Reviews ·Matteo Repetto, Marina Chiara Garassino, Herbert H. Loong, Fernando López‐Ríos, Tony Mok, Solange Peters, David Planchard, Sanjay Popat, Erin R. Rudzinski, Alexander Drilon, Caicun Zhou	2024	7
6	Sotorasib versus pembrolizumab in combination with platinum doublet chemotherapy as first-line treatment for metastatic or locally advanced, PD-L1 negative, KRAS G12C-mutated NSCLC (CodeBreaK 202). Journal of Clinical Oncology ·Fabrice Barlési, Enriqueta Felip, Sanjay Popat, Benjamin Solomon, Juergen Wolf, Bob T. Li, Yi‐Long Wu, Keith M. Kerr, Hiroaki Akamatsu, David Ross Camidge, Ravi G. Gupta, Alison R. Meloni, Tian Dai, Hossein Borghaei	2024	4
7	118MO Trastuzumab deruxtecan (T-DXd) and pembrolizumab in immuno-oncology (IO)-naive HER2-expressing or HER2-mutant non-small cell lung cancer (NSCLC): Interim analysis of a phase Ib study Immuno-Oncology Technology ·Antoine Italiano, B. Besse, Hossein Borghaei, Sanjay Popat, Geòrgia Anguera, Anthony Gonçalvès, Marie Meurer, Julien Mazières, Christos Chouaid, J. Soberino García, (unknown), Antonio Calles, David Vicente Baz, Michael Chisamore, Daniel Barrios, Kazuhiro Abe, Dipica Haribhai, Mark Rosen, Bruce L. Cunningham, Luis Paz‐Ares	2024	3
8	FURVENT: Phase 3 trial of firmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertion mutations (FURMO-004) Lung Cancer ·Alexander I. Spira, Byoung Chul Cho, Enriqueta Felip, Edward B. Garon, Kōichi Goto, Melissa Johnson, Natasha B. Leighl, Antonio Passaro, David Planchard, Sanjay Popat, James Chih‐Hsin Yang, Xiaoqian Lu, Yong Jiang, Jack Huang, Morgan Lam, Marcin Kowanetz, Shirley Wang, John T. Le, Jerry Y. Hsu, Caicun Zhou	2024	2
9	Successful Lorlatinib Rechallenge After Severe Drug-Induced Psychosis in ALK-Positive Metastatic NSCLC: A Case Report JTO Clinical and Research Reports ·Alexius John, Joanna Vick, Sarah Sarker, Elizabeth M. Middleton, Elizabeth Cartwright, Thubeena Manickavasagar, David McMahon, Nadza Tokaca, Sanjay Popat	2024	1
10	PP01.24 FURVENT: Phase 3 trial testing furmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertions (FURMO-004) Journal of Thoracic Oncology ·Alexander I. Spira, Byoung Chul Cho, Enriqueta Felip, Edward B. Garon, Kōichi Goto, Melissa Johnson, Natasha B. Leighl, Antonio Passaro, David Planchard, Sanjay Popat, James Chih‐Hsin Yang, Xiaoqian Lu, Yong Jiang, Jack Huang, Morgan Lam, Marcin Kowanetz, Shirley Wang, John T. Le, Jerry Y. Hsu, Caicun Zhou	2024	0
11	LBA15 Amivantamab plus chemotherapy (with or without lazertinib) vs chemotherapy in EGFR-mutated advanced NSCLC after progression on osimertinib: MARIPOSA-2, a phase III, global, randomized, controlled trial Annals of Oncology ·Antonio Passaro, Byoung Chul Cho, Yan Wang, Barbara Melosky, Raffaele Califano, SH Lee, Nicolas Girard, Karen L. Reckamp, Toshiaki Takahashi, Enriqueta Felip, Ryan D. Gentzler, Sanjay Popat, William N. William, Tao Sun, Shalin Shah, B. Diorio, Roland E. Knoblauch, Joshua Bauml, M.R. García-Campelo, Jing Wang	2023	8
12	LBA63 SAPPHIRE: Phase III study of sitravatinib plus nivolumab versus docetaxel in patients with previously treated advanced non-squamous non-small cell lung cancer (NSCLC) Annals of Oncology ·Hossein Borghaei, Melissa L. Johnson, Edward B. Garon, Kai He, David Planchard, Martin Reck, Sanjay Popat, Roy S. Herbst, Ticiana Leal, Daphne W. Dumoulin, Filippo de Marinis, Charles H. Reynolds, Willemijn S.M.E. Theelen, Ivor Percent, V. Gutiérrez Calderón, A-C. Madroszyk Flandin, Ronald Shazer, Xin Yan, R. Harrigan, S. Peters	2023	4
13	LBA5 Amivantamab plus chemotherapy vs chemotherapy as first-line treatment in EGFR Exon 20 insertion-mutated advanced non-small cell lung cancer (NSCLC): Primary results from PAPILLON, a randomized phase III global study Annals of Oncology ·N. Girard, K. Park, Kun Tang, Byoung Chul Cho, Luis Paz‐Ares, Sunfa Cheng, Satoru Kitazono, M. Thiagarajan, J.W. Goldman, Joshua K. Sabari, Rachel E. Sanborn, Aaron S. Mansfield, J-Y. Hung, Sanjay Popat, Josiane Mourão Dias, A. Bhattacharya, Tanu Agrawal, Martin Shreeve, Roland E. Knoblauch, Caicun Zhou	2023	5
14	Health-related quality of life in the randomized phase III trial of brigatinib vs crizotinib in advanced ALK inhibitor–naive ALK + non−small cell lung cancer (ALTA-1L) Lung Cancer ·M.R. García Campelo, Huamao Mark Lin, Yanyan Zhu, M. Pérol, Mohammad Jahanzeb, Sanjay Popat, Pingkuan Zhang, D. Ross Camidge	2021	12
15	Safety monitoring of two and four-weekly adjuvant durvalumab for patients with stage III NSCLC: implications for the COVID-19 pandemic and beyond Lung Cancer ·Kroopa Joshi, Abdul Muhith, Mariam Obeid, Charlotte Milner-Watts, Nadia Yousaf, Sanjay Popat, Michael Davidson, Jaishree Bhosle, Mary O’Brien, Anna Minchom	2021	5
16	Effectiveness and safety of immunotherapy in NSCLC patients with ECOG PS score ≥2 – Systematic review and meta-analysis Lung Cancer ·Bartłomiej Tomasik, Michał Bieńkowski, Marcin Braun, Sanjay Popat, Rafał Dziadziuszko	2021	39
17	Presence of pleomorphic features but not growth patterns improves prognostic stratification of epithelioid malignant pleural mesothelioma by 2‐tier nuclear grade Histopathology ·Yu Zhi Zhang, Cecilia Brambilla, Philip L. Molyneaux, Alexandra Rice, Jan Lukas Robertus, Simon Jordan, Eric Lim, Loı̈c Lang-Lazdunski, Sofina Begum, Michael Dusmet, Vladimir Anikin, Emma Beddow, Jonathan Finch, Nizar Asadi, Sanjay Popat, John Le Quesne, Aliya N. Husain, William Cookson, Miriam F. Moffatt, Andrew G. Nicholson	2020	9
18	Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial Journal of Clinical Oncology ·Federica Grosso, Nicola Steele, Silvia Novello, Anna K. Nowak, Sanjay Popat, Laurent Greillier, Thomas John, Natasha B. Leighl, Martin Reck, Paul Taylor, David Planchard, Jens Benn Sørensen, Mark A. Socinski, Ute von Wangenheim, Arsène Bienvenu Loembé, José Barrueco, Nassim Morsli, Giorgio V. Scagliotti	2017	77
19	First-line afatinib versus chemotherapy in patients with non-small cell lung cancer and common epidermal growth factor receptor gene mutations and brain metastases QUT ePrints (Queensland University of Technology) ·Martin Schüler, Yi‐Long Wu, Vera Hirsh, Kenneth J. O’Byrne, Nobuyuki Yamamoto, Tony Mok, Sanjay Popat, Lecia V. Sequist, Dan Massey, Victoria Zazulina, James Chih‐Hsin Yang	2016	1
20	Tailoring Microbial Electrochemical Cells for Production of Hydrogen Peroxide at High Concentrations and Efficiencies ChemSusChem ·Michelle Young, Mikaela J. Links, Sanjay Popat, Bruce E. Rittmann, César I. Torres	2016	69

About Sanjay Popat

Sanjay Popat is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Cancer Research, Gastroenterology and Pathology and Forensic Medicine, having authored 372 papers that have together received 13.5k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (218 papers), Lung Cancer Research Studies (84 papers), Lung Cancer Diagnosis and Treatment (72 papers), Colorectal Cancer Treatments and Studies (62 papers), Cancer Genomics and Diagnostics (51 papers), Occupational and environmental lung diseases (49 papers), Cancer Immunotherapy and Biomarkers (41 papers) and Pleural and Pulmonary Diseases (29 papers). The work is most often cited by research in Oncology (8.1k citations), Pulmonary and Respiratory Medicine (8.3k citations), Cancer Research (2.6k citations), Pathology and Forensic Medicine (2.1k citations) and Otorhinolaryngology (217 citations). Sanjay Popat has collaborated with scholars based in United Kingdom, United States and France. Frequent co-authors include Richard S. Houlston, Solange Peters, Richard Hubner, Keith M. Kerr, Martin Reck, Silvia Novello, Tony Mok, Corinne Faivre‐Finn, Dirk De Ruysscher and Fabrice Barlési. Their work appears in journals such as Annals of Oncology, Lung Cancer, Journal of Clinical Oncology, Journal of Thoracic Oncology and European Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact